OmniAb Inc. Asset Resilience Ratio
OmniAb Inc. asset resilience ratio. OmniAb Inc. (OABI) has an Asset Resilience Ratio of 14.21% as of September 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See OABI days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of OmniAb Inc. (2021–2025)
Asset resilience ratio of OmniAb Inc. from 2021 to 2025. This chart shows how OmniAb Inc.'s Asset Resilience Ratio has changed over time. Read OABI total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down OmniAb Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see OmniAb Inc. assets under control.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $41.33 Million | 14.21% |
| Total Liquid Assets | $41.33 Million | 14.21% |
Asset Resilience Insights
- Moderate Liquidity: OmniAb Inc. has 14.21% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
OmniAb Inc. Industry Peers by Asset Resilience Ratio
Compare OmniAb Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 10.35% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
|
DNA Link Inc
KQ:127120 |
Biotechnology | 0.00% |
OmniAb Inc. Asset Resilience Ratio by Year (2021–2025)
OmniAb Inc. asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for OmniAb Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 9.47% | $28.50 Million | $300.91 Million | -0.31pp |
| 2024-12-31 | 9.78% | $31.84 Million | $325.56 Million | -9.04pp |
| 2023-12-31 | 18.82% | $70.62 Million | $375.23 Million | +5.79pp |
| 2022-12-31 | 13.03% | $54.88 Million | $421.21 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $304.46 Million | -- |
About OmniAb Inc.
OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partne… Read more